701 VETERANS CIRCLE, WARMINSTER, PA
Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
Claim Construction Order
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
Shareholder votes
Reports First Quarter 2025 Financial Results and Provides Corporate Update
Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
To Present Imdusiran and AB-101 Data at EASL Congress 2025
Q2
Q1
FY 2024
Q3
FY 2023
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload